Rallybio Corporation (NASDAQ:RLYB) Receives Average Rating of “Reduce” from Brokerages

Rallybio Corporation (NASDAQ:RLYB) has been assigned an average recommendation of “Reduce” from the five ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company.

Several research firms have recently weighed in on RLYB. Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Wall Street Zen raised shares of Rallybio to a “hold” rating in a research report on Saturday.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd raised its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after buying an additional 38,205 shares during the last quarter. Renaissance Technologies LLC grew its position in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares in the last quarter. Geode Capital Management LLC grew its position in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares in the last quarter. Susquehanna International Group LLP increased its stake in Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares during the period. Finally, Citadel Advisors LLC increased its stake in Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares during the period. Institutional investors own 90.34% of the company’s stock.

Rallybio Stock Performance

NASDAQ RLYB opened at $8.22 on Friday. The stock has a 50-day simple moving average of $6.97 and a 200 day simple moving average of $5.78. Rallybio has a twelve month low of $1.76 and a twelve month high of $11.49. The stock has a market capitalization of $43.48 million, a PE ratio of -3.21 and a beta of -1.13.

Rallybio (NASDAQ:RLYB) last released its earnings results on Thursday, March 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.01. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.10 million. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%. As a group, equities research analysts forecast that Rallybio will post -1.34 EPS for the current fiscal year.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.